Urokinase-Type Plasminogen Activator
"Urokinase-Type Plasminogen Activator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES.
Below are MeSH descriptors whose meaning is more general than "Urokinase-Type Plasminogen Activator".
Below are MeSH descriptors whose meaning is more specific than "Urokinase-Type Plasminogen Activator".
This graph shows the total number of publications written about "Urokinase-Type Plasminogen Activator" by people in this website by year, and whether "Urokinase-Type Plasminogen Activator" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Urokinase-Type Plasminogen Activator" by people in Profiles.
Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography. J Control Release. 2016 06 10; 231:60-7.
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells. Anticancer Res. 2015 Oct; 35(10):5263-70.
The NuRD chromatin-remodeling enzyme CHD4 promotes embryonic vascular integrity by transcriptionally regulating extracellular matrix proteolysis. PLoS Genet. 2013; 9(12):e1004031.
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Jun; 125(3):635-9.
Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells. Biochem Cell Biol. 2008 Dec; 86(6):477-86.
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008 Oct; 111(1):89-94.
Cost-effectiveness of urokinase and alteplase for treatment of acute peripheral artery disease: comparison in a decision analysis model. Am J Health Syst Pharm. 2008 Aug 01; 65(15):1435-42.
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol. 2005 Oct; 99(1):50-7.
The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells. Clin Exp Metastasis. 1998 Apr; 16(3):235-41.
Frequency of a normal lung scan observed in the urokinase-streptokinase pulmonary embolism trial. Invest Radiol. 1987 Apr; 22(4):357.